Boston Scientific Corporation (NYSE:BSX): Leerink notes that according to its website, the FDA has scheduled a Circulatory System Device Panel on April 26 to discuss Cameron Health’s S-ICD system. Leerink believes the move suggests the FDA has a positive bias toward the technology, and notes Boston Scientific (NYSE:BSX) is in the process of acquiring Cameron. Further, Leerink views Cameron taking the April 26 date suggests continued delay for Edwards Lifesciences’ (NYSE:EW) high risk patients premarket approval applications. Leerink attributes the weakness in Edwards Lifesciences shares today to this news, and feels the FDA panel is a positive surprise for Boston Scientific.
Apple Inc. (NASDAQ:AAPL): Apple price target raised to $700 from $660 at Goldman.
Gordmans Stores, Inc. (NASDAQ:GMAN): Gordmans Stores sees Q1 EPS 40-41c, consensus 40c.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com